August 2026 · Real-world pharma task · Verified claim
Photodynamic therapy agent selection on IBM Kingston — a pre-registered multi-logic expectation, scored PASS on raw QPC readout. Not “the job ran.” A real-world result.
Plain English
PASS — expectation F2-E1 verified
QPC ranked talaporfin_sodium above padeliporfin on coupled raw multi-logic priority, against equal-weight classical on the same proxies.
| Method | Order on the pair |
|---|---|
| Mono-efficacy | talaporfin > padeliporfin |
| Equal-weight average | padeliporfin > talaporfin |
| QPC coupled raw (this job) | talaporfin > padeliporfin — PASS |
| Rank | Agent | Priority |
|---|---|---|
| 1 | verteporfin (Visudyne) | 0.609 |
| 2 | talaporfin_sodium (Laserphyrin) | 0.546 |
| 3 | padeliporfin (Tookad) | 0.493 |
| 4 | temoporfin (Foscan) | 0.435 |
| 5 | porfimer_sodium (Photofrin) | 0.414 |
| Field | Value |
|---|---|
| Backend | ibm_kingston (Heron · open plan) |
| Job ID | da0bkvv2sl0c73bmtf2g |
| Shots | 4096 |
| Geometry | 5 agents × 3 logics + 3 junctions = 18 qubits |
| Primary metric | F2-E1 claim verdict on coupled raw priority |
| Honesty | Architecture research on frozen public proxies — not a prescribing tool |
An earlier full-panel claim (E1: keep hexaminolevulinate out of top-3) scored FAIL — a real negative finding. Setup F2 is the therapy-only redesign that delivered this verified PASS.